How Eli Lilly’s CEO Plans to Defeat Pharma’s Boom-Bust Cycle
Affected assets and topics
Article tone
Expected market reaction
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- free-analysis-rule-based-analysis
- Analysis version
- free-analysis-rule-based-analysis
- Article id
- 99222
Original source
When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly’s 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company’s hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look. (Source: Bloomberg)
Read the full article on Bloomberg
Original article published by Bloomberg on June 23, 2026. Analysis and insights provided by AnalystMarkets AI.
This model on similar stories
Free Analysis Rule Based Analysis · 37.9% correct across 66 scored calls on indices See the full record